ClinicalTrials.govpublic full text
Study of Nighttime Dosing of Sublingual Tizanidine (12 mg) in Multiple Sclerosis (MS) Patients With Significant Spasticity
muscle spasticity, multiple sclerosis, spasticity, sublingual tizanidine, ashworth scores, spasticity in multiple sclerosis patients, interventional, phase1, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 864731
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.